Ipilimumab

Ipilimumab Reactions 1704, p207 - 2 Jun 2018 Sweet syndrome: case report A 79-year-old man developed Sweet syndrome during treatment with ipilimumab for metastatic melanoma [route not stated]. The man presented with several tender and purpuric plaques on the left hand, generalised malaise and fever. He had a history of stage IV BRAF wild-type metastatic melanoma with nodal, cerebral and pulmonary metastases and had been receiving therapy with ipilimumab 3 mg/kg every three weeks. He had received four doses before the onset of the cutaneous manifestations. A histopathological examination of a punch biopsy from his left hand showed an intensely neutrophilic dermal infiltrate with oedema, consistent with Sweet syndrome. A full blood examination showed leucocytosis and anaemia. He had a mildly elevated CRP level of 26 mg/dL. The man’s ipilimumab therapy was discontinued. He was treated with prednisolone and betamethasone dipropionate, and complete resolution of the cutaneous lesions was noted. He then started receiving nivolumab for the melanoma. Author comment: "In our case, the characteristic histopathological findings and temporally-related resolution with withdrawal of the drug support a diagnosis of ipilimumab-associated [Sweet syndrome], representing the fourth reported case in the scientific literature." Adler NR, et al. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma. Clinical and Experimental Dermatology 43: 497-499, No. 4, Jun 2018. Available from: URL: http://doi.org/10.1111/ced.13399 - Australia 803323462 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Ipilimumab

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/ipilimumab-ylVcUVK0rJ
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46850-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p207 - 2 Jun 2018 Sweet syndrome: case report A 79-year-old man developed Sweet syndrome during treatment with ipilimumab for metastatic melanoma [route not stated]. The man presented with several tender and purpuric plaques on the left hand, generalised malaise and fever. He had a history of stage IV BRAF wild-type metastatic melanoma with nodal, cerebral and pulmonary metastases and had been receiving therapy with ipilimumab 3 mg/kg every three weeks. He had received four doses before the onset of the cutaneous manifestations. A histopathological examination of a punch biopsy from his left hand showed an intensely neutrophilic dermal infiltrate with oedema, consistent with Sweet syndrome. A full blood examination showed leucocytosis and anaemia. He had a mildly elevated CRP level of 26 mg/dL. The man’s ipilimumab therapy was discontinued. He was treated with prednisolone and betamethasone dipropionate, and complete resolution of the cutaneous lesions was noted. He then started receiving nivolumab for the melanoma. Author comment: "In our case, the characteristic histopathological findings and temporally-related resolution with withdrawal of the drug support a diagnosis of ipilimumab-associated [Sweet syndrome], representing the fourth reported case in the scientific literature." Adler NR, et al. Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma. Clinical and Experimental Dermatology 43: 497-499, No. 4, Jun 2018. Available from: URL: http://doi.org/10.1111/ced.13399 - Australia 803323462 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off